HUSA, Petr, Svatava SNOPKOVÁ, Jiřina ZAVŘELOVÁ, Filip ZLÁMAL, Radek SVAČINKA and Petr HUSA. Circulating microparticles in patients with chronic hepatitis C and changes during direct-acting antiviral therapy. Biomedical Papers. Olomouc: Univerzita Palackého v Olomouci, 2021, vol. 165, No 2, p. 146-151. ISSN 1213-8118. Available from: https://dx.doi.org/10.5507/bp.2021.023.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Circulating microparticles in patients with chronic hepatitis C and changes during direct-acting antiviral therapy
Authors HUSA, Petr (203 Czech Republic, guarantor, belonging to the institution), Svatava SNOPKOVÁ (203 Czech Republic, belonging to the institution), Jiřina ZAVŘELOVÁ (203 Czech Republic), Filip ZLÁMAL (203 Czech Republic, belonging to the institution), Radek SVAČINKA (203 Czech Republic, belonging to the institution) and Petr HUSA (203 Czech Republic, belonging to the institution).
Edition Biomedical Papers, Olomouc, Univerzita Palackého v Olomouci, 2021, 1213-8118.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 20601 Medical engineering
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 1.648
RIV identification code RIV/00216224:14110/21:00121463
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.5507/bp.2021.023
UT WoS 000660244900005
Keywords in English microparticles; microvesicles; chronic hepatitis C; direct-acting antivirotics
Tags 14110214, podil, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 17/5/2022 09:03.
Abstract
Background. Microparticles (MPs) are heterogeneous vesicles derived from membranes of different cells. Between 70 to 90% of MPs detected in blood originate from platelets. The release of MPs is associated with proinflammatory and procoagulant states. Elevated levels of MPs have been found in different diseases. We investigated MPs levels in patients with chronic hepatitis C (CHC) and changes in level during treatment using direct-acting antivirotics (DAA). Patients and Methods. Thirty-six patients with CHC and forty healthy volunteers were included in the study. Concentrations of MPs were determined indirectly by measuring their procoagulant activity in plasma at baseline, end of therapy (EOT), and 12 weeks after EOT when the sustained virological response was assessed (SVR12). Results. All patients achieved SVR12, which was associated with rapid improvement of markers of liver damage and function as well as liver stiffness (P=0.002). MPs levels were significantly higher in CHC patients than in healthy volunteers (P<0.001). No statistically significant decrease was found observed between baseline and SVR12 (P=0.330). Analysis of subpopulations with minimal fibrosis F0-1 (P=0.647), advanced fibrosis F2-4 (P=0.370), women(P=0.847), men (P=0.164) and genotype 1 (P=0.077) showed no significant changes during the follow-up period. Conclusions. MPs levels are higher in CHC patients and remain elevated shortly after achieving SVR. Higher concentrations of MPs in plasma are probably caused by a chronic uncontrolled exaggerated inflammatory response caused by CHC. Longer observation would probably confirm the significance of MPs levels decrease because normalization of liver function, inflammation, and structure after SVR requires more than 12 weeks.
PrintDisplayed: 24/4/2024 14:33